论文部分内容阅读
据澳大利亚“全国第二次血压研究(ANBP2)”报告,在血压降低的相同情况下,血管紧张素转化酶抑制剂(ACEI)在降低心血管事件方面要优于利尿剂。这个发现与应用“抗高血压和降脂治疗来预防心脏病发作的试验(ALLHAT)”结果正好相反,该试验结果认为利尿剂更为有效。 ANBP2进行的是一项前瞻性的随机开放标记性研究,平均随访期为4.1年,应用盲法终点法评价了6,083名65～84岁的高血压患者。在研究结束
According to Australia’s National Second Blood Pressure Study (ANBP2), angiotensin converting enzyme inhibitors (ACEIs) are superior to diuretics in reducing cardiovascular events in the same context of reduced blood pressure. This finding is in contrast to the results of the “Antihypertensive and lipid-lowering treatment to prevent heart attack (ALLHAT)” trial, which concluded that diuretics are more effective. ANBP2 was a prospective, randomized open-label study with an average follow-up of 4.1 years and evaluated 6,083 hypertensive patients aged 65-84 years using the blinded endpoint method. At the end of the study